MGI Pharma MOGN New patents, anti cancer Message Board

Sponsor

From: Icebrg	10/22/2004 1:29:22 AM
	Read Replies (2) of 1824

MGI Pharma initiated with "neutral weight" - update Thursday, October 21, 2004 4:39:17 AM ET Prudential Financial NEW YORK, October 21 (newratings.com) - Analyst Jason Zhang of Prudential Financial initiates coverage of MGI Pharma Inc (MOGN.NAS) with a "neutral weight" rating. The 12-18 month target price is set to $30. In a research note published yesterday, the analyst mentions that the company is poised to benefit in the forthcoming years from its key product, Aloxi, for the treatment of chemotherapy-induced nausea and vomiting (CINV). MGI Pharma's stock performance is likely to be driven in the near term by Dacogen's regulatory progress, the ongoing clinical trials for the recently acquired products and Aloxi's sales, the analyst says. Prudential Financial believes, however, that the company stock is fairly valued at present.